Select a State

Global health R&D delivers for New York

US government investment in global health R&D has delivered

$916.0 million
to New York research institutions
9,600+ new jobs
for New York
4480

Neglected diseases in New York

Chikungunya cases
955
Dengue cases
818
HIV diagnoses
33399
Malaria cases
2025
Tuberculosis cases
8090
West Nile cases
469
Zika cases
1065

New York

--

New York's top USG-funded global health R&D institutions

International AIDS Vaccine Initiative
$ 302.4 million
Cornell University (including Weill Cornell Medical College)
$ 96.5 million
Yeshiva University (including Albert Einstein College of Medicine)
$ 95.3 million
Population Council
$ 78 million
New York University School of Medicine
$ 72 million
TB Alliance
$ 36.2 million
Rockefeller University
$ 32.6 million
Columbia University (including Health Sciences)
$ 30 million
University of Rochester
$ 25.9 million
Icahn School of Medicine at Mount Sinai (formerly the Mount Sinai School of Medicine)
$ 24.7 million

New York industry in global health R&D

BASF Corporation
Location(s):
Tarrytown
Bristol-Myers Squibb
Location(s):
New York City, Syracuse
Buffalo BioLabs
Location(s):
Buffalo
Charles River Laboratories
Location(s):
Kingston
Chembio Diagnostic Systems
Location(s):
Medford
Cipla
Location(s):
Central Islip
Codagenix
Location(s):
Farmingdale
Disease Diagnostic Group
Location(s):
Buffalo
Eli Lilly and Company
Location(s):
New York City
J-LABS
Location(s):
New York City
item[company]
Location(s):
Brooklyn
item[company]
Location(s):
New York City
item[company]
Location(s):
New York City, Melville, Suffern
item[company]
Location(s):
Rochester
item[company]
Location(s):
New York City, Pearl River
item[company]
Location(s):
Tarrytown
item[company]
Location(s):
Rensselaer
item[company]
Location(s):
Rensselaer, Sleepy Hollow, Tarrytown
item[company]
Location(s):
New York City
item[company]
Location(s):
Tarrytown
item[company]
Location(s):
Hauppauge
item[company]
Location(s):
Rockville Centre
item[company]
Location(s):
Buffalo

New York's top areas of global health R&D by USG funding

54.4%
HIV/AIDS
8.3%
Malaria
23.1%
Tuberculosis
1.4%
Diarrheal diseases
1.4%
Ebola/viral hemorrhagic fevers
6.7%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
Leprosy
4.7%
Other
Bacteria pneumonia & meningitis
Cryptococcal meningitis
Non-allocable
Salmonella infections
Rheumatic fever

Global health R&D at work in New York

The International AIDS Vaccine Initiative (IAVI) is working to develop HIV vaccines and other prevention tools. Research by IAVI and partners has yielded insights into how the immune system attempts to control the virus, how HIV evades immune defenses, how disease progression varies by virus strain, and how some people living with HIV naturally produce antibodies against a broad array of HIV types. IAVI is supporting development and testing of 11 vaccine candidates.

Footnotes